Related Experiment Video

Updated: Oct 5, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.1K

Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma

Ying Zhou1, Xiaohong Xu1

  • 1Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, People's Republic of China.

Hematology (Amsterdam, Netherlands)
|January 24, 2022
PubMed

Insights

Patients with relapsed or refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) have a poor prognosis. This review explores targeted drugs that could offer new therapeutic strategies for PCNSL.

Area of Science:

  • Oncology
  • Hematology
  • Genomics

Background:

  • Relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) presents a significant clinical challenge with a poor prognosis.
  • Currently, no standard salvage treatment exists for patients with relapsed/refractory PCNSL.

Purpose of the Study:

  • To review targeted drugs with the potential to alter the treatment paradigm for PCNSL.
  • To explore novel therapeutic avenues based on recent advancements in understanding PCNSL pathogenesis.

Main Methods:

  • Comprehensive literature review of targeted therapies.
  • Analysis of gene expression profiling and next-generation sequencing data in PCNSL.
  • Evaluation of potential therapeutic mechanisms identified through molecular profiling.

Main Results:

  • Gene expression profiling and next-generation sequencing have elucidated key pathogenic mechanisms in PCNSL.
  • Several targeted drug candidates show promise for therapeutic intervention.
  • Emerging data suggests potential for personalized treatment approaches.

Conclusions:

  • Targeted therapies represent a promising frontier for improving outcomes in relapsed/refractory PCNSL.
  • Further research and clinical trials are warranted to validate the efficacy of these agents.
  • Advancements in molecular understanding are paving the way for more effective PCNSL treatments.
Keywords:
BTK inhibitorsPCNSLPI3  K/mTOR inhibitorsimmune checkpoint inhibitorsimmunomodulatorsrelapsed and refractory

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711